Advertisement
UK markets closed
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • FTSE 250

    19,884.73
    +74.07 (+0.37%)
     
  • AIM

    743.26
    +1.15 (+0.15%)
     
  • GBP/EUR

    1.1696
    +0.0003 (+0.02%)
     
  • GBP/USD

    1.2618
    -0.0004 (-0.03%)
     
  • Bitcoin GBP

    55,584.10
    -269.83 (-0.48%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • DOW

    39,807.37
    +47.29 (+0.12%)
     
  • CRUDE OIL

    83.11
    -0.06 (-0.07%)
     
  • GOLD FUTURES

    2,254.80
    +16.40 (+0.73%)
     
  • NIKKEI 225

    40,369.44
    +201.37 (+0.50%)
     
  • HANG SENG

    16,541.42
    +148.58 (+0.91%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • CAC 40

    8,205.81
    +1.00 (+0.01%)
     

Analyzing Novartis’s Alcon over Recent Quarters

Analyzing Novartis’s Alcon over Recent Quarters

Alcon, Novartis’s (NVS) eyecare business, includes surgical and vision care products. In Q1 2018, Alcon revenue grew 12% YoY (year-over-year) to ~$1.8 billion from ~$1.6 billion, driven by 7% operating revenue growth and boosted by 5% due to foreign exchange. The chart below shows Alcon’s revenue since Q1 2017.